CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Avastin (with capecitabine) for Metastatic Colorectal Cancer - Details

Project Number PC0055-000
Brand Name Avastin (with capecitabine)
Generic Name Bevacizumab
Strength 25 mg/mL
Tumour Type Gastrointestinal
Indication Metastatic Colorectal Cancer
Funding Request In combination with capecitabine, for the first-line treatment of advanced or metastatic colorectal cancer (CRC) for patients who are not suitable for oxaliplatin or irinotecan-based therapy
Review Status Complete
Pre Noc Submission No
NOC Date September 5, 2005
Manufacturer Hoffmann-La Roche Limited
Sponsor Cancer Care Ontario Gastrointestinal Disease Site Group
Submission Date February 18, 2015
Submission Deemed Complete February 25, 2015
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ March 4, 2015
Check-point meeting April 20, 2015
pERC Meeting June 18, 2015
Initial Recommendation Issued July 3, 2015
Feedback Deadline ‡ July 17, 2015
Final Recommendation Issued July 21, 2015
Notification to Implement Issued August 6, 2015
Therapeutic Area Metastatic Colorectal Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.